Publications by authors named "Richard Hartz"

Claim this Profile
I
Invention of VH-937, a Potent HIV-1 Maturation Inhibitor with the Potential for Infrequent Oral Dosing in Humans.
Sing-Yuen Sit, Yan Chen, Jie Chen, Brian L Venables, Jacob J Swidorski, Richard A Hartz

ACS Med Chem Lett· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937.
Brian McAuliffe, Paul Falk, Jie Chen, Yan Chen, Sing-Yuen Sit, Richard A Hartz

Viruses· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atropisomerism Observed in Galactose-Based Monosaccharide Inhibitors of Galectin-3 Comprising 2-Methyl-4-phenyl-2,4-dihydro-3-1,2,4-triazole-3-thione.
David S Yoon, Chunjian Liu, Prasada Rao Jalagam, Jianxin Feng, Wei Wang, Richard A Hartz

J Med Chem· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors.
Richard A Hartz, Vijay T Ahuja, Guanglin Luo, Ling Chen, Prasanna Sivaprakasam

J Med Chem· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Structure-Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors.
Richard A Hartz, Vijay T Ahuja, Prasanna Sivaprakasam, Hong Xiao, Carol M Krause

J Med Chem· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, Structure-Activity Relationships, and Evaluation of Novel C-17 Amine Derivatives Based on GSK3640254 as HIV-1 Maturation Inhibitors with Broad Spectrum Activity.
Richard A Hartz, Li Xu, Sing-Yuen Sit, Jie Chen, Brian L Venables

J Med Chem· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 Maturation.
Alicia Regueiro-Ren, Sing-Yuen Sit, Yan Chen, Jie Chen, Jacob J Swidorski, Richard A Hartz

J Med Chem· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bicyclic Heterocyclic Replacement of an Aryl Amide Leading to Potent and Kinase-Selective Adaptor Protein 2-Associated Kinase 1 Inhibitors.
Richard A Hartz, Vijay T Ahuja, Susheel J Nara, C M Vijaya Kumar, Raju K V L P Manepalli

J Med Chem· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain.
Richard A Hartz, Vijay T Ahuja, Susheel J Nara, C M Vijaya Kumar, Jeffrey M Brown

J Med Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, Structure-Activity Relationships, and In Vivo Evaluation of Novel Tetrahydropyran-Based Thiodisaccharide Mimics as Galectin-3 Inhibitors.
Li Xu, Richard A Hartz, Brett R Beno, Kaushik Ghosh, Jinal K Shukla

J Med Chem· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of prodrugs of corticotropin-releasing factor-1 (CRF) receptor antagonist BMS-665053 leading to improved oral bioavailability.
Richard A Hartz, Vivekananda M Vrudhula, Vijay T Ahuja, James E Grace, Nicholas J Lodge

Bioorg Med Chem Lett· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of polymeric nanoparticles for treatment of partial injury to the central nervous system.
Ivan Lozić, Richard V Hartz, Carole A Bartlett, Jeremy A Shaw, Michael Archer

Data Brief· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of carbamate and aryl ether substituted pyrazinones as corticotropin releasing factor-1 (CRF₁) receptor antagonists.
Vijay T Ahuja, Richard A Hartz, Thaddeus F Molski, Gail K Mattson, Kimberley A Lentz

Bioorg Med Chem Lett· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and evaluation of phenylglycinols and phenyl amines as agonists of GPR88.
Carolyn D Dzierba, Yingzhi Bi, Bireshwar Dasgupta, Richard A Hartz, Vijay Ahuja

Bioorg Med Chem Lett· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Method for the assessment of effects of a range of wavelengths and intensities of red/near-infrared light therapy on oxidative stress in vitro.
Marcus K Giacci, Nathan S Hart, Richard V Hartz, Alan R Harvey, Stuart I Hodgetts

J Vis Exp· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological and behavioral characterization of the novel CRF1 antagonist BMS-763534.
Nicholas J Lodge, Snjezana Lelas, Yu-Wen Li, Thaddeus Molski, James Grace, Richard Hartz

Neuropharmacology· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential CRF1R PET imaging agents: 1-fluoroalkylsubstituted 5-halo-3-(arylamino)pyrazin-2(1H)-ones.
Derek J Denhart, Dmitry Zuev, Jonathan L Ditta, Richard A Hartz, Vijay T Ahuja

Bioorg Med Chem Lett· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agents.
Jeffrey A Deskus, Douglas D Dischino, Ronald J Mattson, Jonathan L Ditta, Michael F Parker, Richard A Hartz

Bioorg Med Chem Lett· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chiral separation of potent corticotropin-releasing factor-1 receptor antagonists by supercritical fluid chromatography.
Jingfang Qian-Cutrone, Richard Hartz, Vijay T Ahuja, Vivekananda M Vrudhula, Dauh-Rurng Wu

J Pharm Biomed Anal· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Richard A Hartz, Vijay T Ahuja, William D Schmitz, Thaddeus F Molski, Gail K Mattson

Bioorg Med Chem Lett· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative biotransformation of pyrazinone-containing corticotropin-releasing factor receptor-1 antagonists: minimizing the reactive metabolite formation.
Xiaoliang Zhuo, Richard A Hartz, Joanne J Bronson, Harvey Wong, Vijay T Ahuja

Drug Metab Dispos· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
Richard A Hartz, Vijay T Ahuja, Xiaoliang Zhuo, Ronald J Mattson, Derek J Denhart

J Med Chem· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Richard A Hartz, Vijay T Ahuja, Maria Rafalski, William D Schmitz, Allison B Brenner

J Med Chem· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Richard A Hartz, Vijay T Ahuja, Argyrios G Arvanitis, Maria Rafalski, Eddy W Yue

J Med Chem· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands.
Richard A Hartz, Argyrios G Arvanitis, Charles Arnold, Joseph P Rescinito, Kimberly L Hung

Bioorg Med Chem Lett· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis